PAD
Conditions
Keywords
Lower Extremity Arterial Occlusive Disease, Interventional Therapy
Brief summary
Along with the improvement of living standard, the prevalence of Lower extremity arterial occlusive disease (LEAOD) is also increasing, which has become an important cause of lower extremity amputation and greatly affected the patients' life quality. Currently, percutaneous transluminal angioplasty (PTA), including balloon dilatation and stent implantation, has been regarded as the most widely applied and accepted treatment for LEAOD. The therapeutic effects of lower extremity interventional treatment, varied in different reports. It was reported that the therapeutic effects were influenced by some traditional risk factors, including age, gender, smoking, and so on. More risk factors are still unknown. The difference of therapeutic effects, the endpoint events were compared between interventional and conventional treatment group to analyze the effect of interventional treatment on LEAOD and explore its risk factors.
Interventions
Sponsors
Third Military Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, age between 40-90 years old. * Ankle-brachial index(ABI)\<0.9. * Lower extremity arterial CT shows that the arterial stenosis\>50%
Exclusion criteria
* Type 2 diabetes with acute complications. * Type 1 diabetes. * Cerebrovascular diseases in the last 3 months. * Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last 3 months. * Hemorrhagic disease. * Hypohepatia (AST or AST is twice higher than the upper limit) or cirrhosis, hepatic encephalopathy. * History of dialysis. * Chronic obstructive pulmonary disease (COPD), chronic respiratory failure or hypoxemia. * Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction. * Fertile woman without contraceptives. * Allergic to iodine. * Unable to understanding and follow the study protocol orientations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ankle-brachial index | Change from baseline at 1 year(End of Trial) |
| Mortality(%) | 1 year(End of Trial) |
| Incidence of amputation(%) | 1 year(End of Trial) |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure(mmHg) | Change from baseline at 1 year(End of Trial) |
| HbA1c(%) | Change from baseline at 1 year(End of Trial) |
| triglyceride(mmol/L) | Change from baseline at 1 year(End of Trial) |
| Incidence of major adverse cardiac events (MACE)(%) | 1 year(End of Trial) |
| LDL-c(mmol/L) | Change from baseline at 1 year(End of Trial) |
| HDL-c(mmol/L) | Change from baseline at 1 year(End of Trial) |
| The lower limb transcutaneous oxygen pressure(mmHg) | Change from baseline at 1 year(End of Trial) |
| total cholesterol(mmol/L) | Change from baseline at 1 year(End of Trial) |
| High-sensitive C reactive protein(mg/L) | Change from baseline at 1 year(End of Trial) |
| Fasting plasma glucose(mmol/L) | Change from baseline at 1 year(End of Trial) |
Countries
China
Contacts
Primary ContactYan Zhencheng, MD
Backup ContactZhu Zhiming, MD, PhD
Outcome results
None listed